scholarly journals KI-67 INDEX AND TYPE OF HSP70 EXPRESSION IN THE FORMATION OF PROGNOSTIC GROUPS OF PATIENTS WITH PAPILLARY THYROID CANCER

2018 ◽  
Vol 23 (2) ◽  
pp. 90-95
Author(s):  
Anatoliy A. Ivanov ◽  
A. M Avdalyan ◽  
E. L Lushnikova ◽  
O. P Molodykh ◽  
Yu. N Zorkina ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Survival Rate ◽  
Papillary Thyroid Cancer ◽  
Mixed Type ◽  
Hsp70 Expression ◽  
Papillary Thyroid ◽  
Ki 67 ◽  
Favorable Prognosis ◽  
Prognosis Group ◽  
Cytoplasmic Type

The aim of our work was to determine the possibility of stratification of papillary thyroid cancer (PTC) patients into prognosis groups depending on the Ki-67 index and the type of HSP70 expression. The study included 89 patients with a known prognosis for the period of 2005-2017, treated for PTC over the period of 2005-2013. The immunohistochemical study was carried out with Ki-67 and HSP70 antibodies on the Ventana XT Steiner device using standard protocols. The method of tissue matrices was used to standardize the study. Different variants of PTC, depending on the level of Ki-67 expression in combination with the HSP70 response allowed identifying 3 groups of PTC prognosis. The favorable prognosis group included patients with samples with cytoplasmic type of HSP70 expression and Ki-67 response < 6.3%, with mixed type of HSP70 expression and Ki-67 response < 6.3%, with cytoplasmic HSP70 expression and Ki-67 response > 6.3%. The intermediate prognosis group consisted of patients with tumors with mixed type of HSP70 expression and Ki-67 response > 6.3%, with nuclear HSP70 expression and Ki-67 response < 6.3%. The group of poor prognosis included patients with nuclear HSP70 expression and Ki-67 response > 6.3%. In the group of favorable prognosis, the 10-year survival rate was 89.6 ± 3.5%. In the intermediate prognosis group, the 10-year survival rate was 45 ± 14.5% and in the unfavorable prognosis group, no patient survives 6 years.

scholarly journals FROM VASOMOTOR SYMPTOMS TO SOLID AND INSULAR PAPILLARY THYROID CANCER WITH OXYPHIL VARIANT AREAS

2015 ◽  
Vol 2 (2) ◽  
pp. 87-91
Author(s):  
Mara Cașorte ◽  
Simona Elena Albu ◽  
R. Iorgulescu ◽  
Anda Dumitrașcu ◽  
Dana Terzea ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Tumour Size ◽  
Thyroid Stimulating Hormone ◽  
Detection Methods ◽  
Intermittent Therapy ◽  
Papillary Thyroid ◽  
Ki 67 ◽  
Pathologic Features ◽  
Toxic Goiter

The thyroid cancer had an increasing frequency during the last decades mostly related to better and accessible detection methods. The papillary type has the major epidemiologic impact. We present a case with mixed symptoms before surgery, a rare combination of both thyrotoxicosis and thyroid malignancy and an unusual pathologic report in a 56-year-old female known with total hysterectomy at age of 42, diagnosed with toxic goiter 2 years ago and under intermittent therapy with thiamazol. She presented for unspecific hot flashes and palpitation at gynaecology and she was referred for endocrine evaluation that revealed unspecific cervical compression complains, and a large goiter. The Thyroid-Stimulating Hormone was normal under thiamazol and so were the thyroid antibodies and calcitonin. The computed tomography pointed an isthmus and left lobe nodule of maximum 7.28 cm with mass effect on trachea. Total thyroidectomy was performed without any significant complications. The patient was hospitalised for 4 days (less than 48 hours postoperatively). The pathological report showed a papillary thyroid cancer (stage III) with oxyphil variant and an insular and solid pattern component. A high proliferative index is detected by vessels invasion and a ki-67 of 15 %. She received radioiodine therapy and then she started suppression levothyroxine treatment. The insular and oxyphilic pattern as well as the large tumour size of 6 cm suggest a severe prognosis. On the other hand, it is still a matter of debate whether non-autoimmune hyperthyroidism and solid pathologic features subscribe to the hypothesis of an aggressive cancer phenotype. Lifelong follow up is needed.

scholarly journals Blood prognostic predictors of treatment response for patients with papillary thyroid cancer

2020 ◽  
Vol 40 (10) ◽  
Author(s):  
Xiangxiang Liu ◽  
Zhongke Huang ◽  
Xianghui He ◽  
Xiangqian Zheng ◽  
Qiang Jia ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Poor Prognosis ◽  
Response To Therapy ◽  
Prognostic Indicators ◽  
High Morbidity ◽  
American Thyroid Association ◽  
Papillary Thyroid ◽  
Distribution Width ◽  
Prognosis Group

Abstract Background: Papillary thyroid cancer (PTC) is a very common malignant disease with high morbidity. We needed some pretreatment indicators to help us predict prognosis and guide treatment. We conducted a study about some pretreatment prognostic indicators. Methods: This clinical study recruited 705 postoperative PTC patients (211 males, 494 females). Clinical data before radioactive iodine (RAI) treatment were collected. Patients’ response to therapy were classified into two categories: ‘Good Prognosis Group’ (GPG) and ‘Poor Prognosis Group’ (PPG), according to ‘2015 American Thyroid Association Guidelines’. Differences of indicators between different prognosis groups were compared. Odds ratios (ORs) were calculated by univariate/multiple binary logistic regression models. Difference of body mass index (BMI) changes before and after RAI treatment between different prognosis groups was also compared. Results: A total of 546 (77.45%) belonged to GPG, and 159 (22.55%) belonged to PPG. Platelet (PLT), neutrophil (NEUT), PLT subgroups, and combination of red blood cell distribution width (RDW) and BMI (COR-BMI) were different between two prognosis groups. The significance of the difference between the two groups of BMI disappeared after the Bonferroni correction. PLT and PLT subgroups had detrimental effects on the risk of PPG; T stage had a positive effect on the risk of PPG. PLT subgroup showed a detrimental effect on the risk of PPG when we included additional covariates. Conclusions: We found that lower pretreatment PLT levels may indicate a poor prognosis for PTC. The relationship between platelet-derived growth factor (PDGF) and radiation sensitivity may be the key to this association.

scholarly journals The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer

2021 ◽  
Author(s):  
Helene Lindfors ◽  
Catharina Ihre Lundgren ◽  
Jan Zedenius ◽  
C. Christofer Juhlin ◽  
Ivan Shabo
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Papillary Thyroid Cancer ◽  
Tumor Recurrence ◽  
Lymph Node Ratio ◽  
Papillary Thyroid ◽  
Ki 67 ◽  
Node Ratio ◽  
N Stage

Abstract Background The N stage in papillary thyroid cancer (PTC) is an important prognostic factor based on anatomical localization of cervical lymph nodes (LNs) only and not the extent of lymphatic metastasis. In this retrospective study, the clinical significance of lymph node ratio (LNR) and tumor cell proliferation in relation to the conventional classification of PTC was explored. Methods Patients diagnosed with PTC at the Karolinska University Hospital in Stockholm, Sweden, during the years 2009–2011 were included. The LNR, defined as the number of metastatic LNs divided by the total number of LNs investigated, and the Ki-67 index were analyzed in relation to clinical data. Results The median number of LN removed was 16 with the following N stage distribution: N0 (26%), N1a (45%), and N1b (29%). A Ki-67 index of ≥3% was significantly correlated with the presence of metastases and tumor recurrence with a sensitivity of 50% and specificity of 80% (p = 0.015). Lymph node ratio ≥21% was related to tumor recurrence with sensitivity of 89% and specificity of 70% (p = 0.006). Patients with LN metastases in the lateral cervical compartment only had significantly lower LNR (14.5%) compared to those with both central and lateral cervical metastases (39.5%) (p = 0.004) and exhibited no tumor recurrence. Increased Ki-67 index was significantly related to LNR ≥21% (p = 0.023) but was not associated with N stage. Conclusions The Ki-67 proliferation index and LNR may better reflect the malignant behavior of PTC compared to the anatomical classification of LN metastases solely.

Immunohistochemical Expression of Bcl-2, Ki-67, and p21 in Patients with Papillary Thyroid Cancer

Tumor Biology ◽  
2005 ◽  
Vol 26 (1) ◽  
pp. 50-56 ◽  
Author(s):  
P&auml;ivi Siironen ◽  
Stig Nordling ◽  
Johanna Louhimo ◽  
Reijo Haapiainen ◽  
Caj Haglund
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Immunohistochemical Expression ◽  
Ki 67

scholarly journals THE BRAF MUTATION V600E IN PAPILLARY THYROID CANCER, CLINICAL-MORPHOLOGICALPARALLELES AND PROGNOSIS

2017 ◽  
Vol 22 (1) ◽  
pp. 15-20
Author(s):  
A. A Ivanov ◽  
A. M Avdalyan ◽  
V. J Gerval’d ◽  
E. L Lushnikova ◽  
Yu. N Zorkina ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Nodes ◽  
Papillary Thyroid Cancer ◽  
Braf Mutation ◽  
Negative Impact ◽  
Morphological Characteristics ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Ki 67 ◽  
Regional Lymph Nodes

On the material of the 67 cases of papillary thyroid cancer (PTC) authors executed the study of the interrelationship between the BRAF mutation V600E and the forecast, biomolecular and morphological characteristics of the disease. There was implemented the analysis of samples for the presence of 7 KRAS gene mutations, 4 mutations of the PIK3CA gene, mutation BRAF V600E with the revealing of the interrelationship between such biomolecular markers for proliferation and apoptosis as Ki-67, p53, Bcl2. Also there was performed chromogenic hybridization (CISH method) in situ to study the status of the HER2 gene. There was determined the interrelationship between BRAF mutation V600E and clinical indices of prognosis: tumor sizes, capsule invasion, presence of metastases in regional lymph nodes. In addition, there was evaluated the interrelationship between BRAF mutation V600E and 10-years survival rate. No mutation were identified in KRAS, PI3K genes. BRAF mutation V600E was identified in 50 cases (75%). The frequency of V600E in women accounted of 75 ± 6.4%, in men - 67 ± 27.1%. In patients with the presence of V600E the size of a node was slightly less than in the absence of mutations and in 76% of cases did not reach the average value of 1.8 cm. Invasion into the capsule was identified in 35 ± 12.7% cases with a positive BRAF mutation V600E status and in 56 ± 8.4% - in cases with a negative status. Metastases in regional lymph nodes occurred in 36 ± 11.6% in patients with V600E and in 47 ± 18.9% of cases without this mutation. There was obtained the interrelationship between V600E and Ki-67: the average level of the proliferative activity in the presence of the given mutation was 4.4 ± 0.6%, in the absence - 9.4 ± 3.9%. No interrelationship was obtained between V600E and other biomolecular parameters or this interrelationship was tendentious in character. In terms of 10-years survival the groups with or without V600E statistically did not differ. Based on the data, it was possible to say about the absence of the negative impact of V600E on the prognosis in PTC patients

scholarly journals Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells

2011 ◽  
Vol 210 (1) ◽  
pp. 105-115 ◽  
Author(s):  
N Dilara Zeybek ◽  
Nese Ersoz Gulcelik ◽  
F Figen Kaymaz ◽  
Can Sarisozen ◽  
Imran Vural ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Cancer Cells ◽  
Papillary Thyroid Cancer ◽  
Caspase 3 ◽  
Thyroid Cell ◽  
Papillary Thyroid ◽  
Ki 67 ◽  
Thyroid Cancer Cells

Statins show antiproliferative activity in various cancer cells. The aim of this study was to evaluate the effects of rosuvastatin treatment on papillary thyroid carcinoma. The papillary thyroid carcinoma (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines were treated with rosuvastatin at 12.5, 18.5, 25, 50, 100, and 200 μM concentrations. After 48 and 72 h of rosuvastatin treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Ki-67 immunolabeling, FACS analysis, electron microscopy, caspase-3, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis were performed. Decreased cell viability and G1 phase arrest were detected in papillary thyroid cell line treated with rosuvastatin. Positive immunoreactivity of Ki-67 and dose-dependent increase in S phase on Nthy-ori 3-1 cells were also detected. B-CPAP cells showed intense vacuolisation and autophagosomes with low concentrations and 48 h incubations, while Nthy-ori 3-1 cells showed these changes at higher concentrations. A decrease in the percentage of cells showing autophagy was determined with increasing concentrations of rosuvastatin in B-CPAP cells. Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Apoptotic cells with nuclear condensation and fragmentation were observed in B-CPAP cell line. Rosuvastatin induced autophagic changes in B-CPAP papillary thyroid cancer cells in lower doses and caused a shift from autophagy to apoptosis. Rosuvastatin may be an alternative treatment for refractory papillary thyroid cancer. Further in vivo studies are necessary to clarify the effects of rosuvastatin in papillary thyroid carcinoma and the clinical implications of rosuvastatin treatment.

Sign in / Sign up

Export Citation Format

Share Document